General
Preferred name
TASIMELTEON
Synonyms
VEC-162 ()
BMS-214778 ()
BMS 214778, VEC 162 ()
BMS-214,778 ()
Hetlioz lq ()
Hetlioz ()
Tasimelteon-d5 ()
P&D ID
PD009143
CAS
609799-22-6
1962124-51-1
Tags
available
drug
Approved by
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Insomnia
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Tasimelteon is a melatonin receptor agonist, activating both the MT1 and MT2 receptor subtypes equipotently. and are also melatonin receptor agonist class drugs.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
32
Molecular Weight
245.14
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
3
Aromatic Ring Count
1
cLogP
2.25
TPSA
38.33
Fraction CSP3
0.53
Chiral centers
2.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Proteases/Proteasome
Neuronal Signaling
Target
Melatonin Receptor
MT2 receptor
MT1 receptor
MTNR1A, MTNR1B
MT Receptor
Indication
Non-24-Hour Sleep-Wake Disorder
MOA
Melatonin receptor agonist
Source data
